Typhoid vaccine

Typhoid vaccine

Typhoid vaccine
Vaccine description
Target disease Typhoid
Clinical data
Legal status
CAS number  YesY
ATC code J07 J07 J07

Typhoid vaccines are vaccines developed to prevent typhoid fever.

There are two effective types:[1]

Ty21a is licensed for use from age six years and older. Boosters are recommended every 5 years.[2] The Vi capsular polysaccharide vaccine is licensed for use from age two years and older, and boosters are required every three years.[3]

Almroth Edward Wright developed an effective inactivated whole-cell typhoid vaccine that was introduced in 1896.[1] Due to side-effects its usage was eventually discontinued.[3]

An experimental vaccine called Vi-rEPA has showed promising results in trials so far, indicating higher effectiveness and longer immunity. However, it has yet to be licensed for use.[1] It is on the health system.[4]

Available preparations

  • Vi polysaccharide vaccine: Typhim Vi® (Sanofi Pasteur); Typherix® (GSK)[3]
  • Combined hepatitis A/Vi polysaccharide vaccine: ViATIM® (Sanofi Pasteur); Hepatyrix® (GSK)[3]
  • Ty21a oral vaccine: Vivotif® (Crucell)[3]


  1. ^ a b c Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L (2007). "Vaccines for preventing typhoid fever". Cochrane Database Syst Rev (3): CD001261.  
  2. ^ http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142807.pdf
  3. ^ a b c d e Salisbury, D; Ramsay, M; Noakes, K. ""Chapter 33: Typhoid"". Immunisation against infectious disease. Department of Health. p. 418.  
  4. ^ "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.